PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 52 | 2 | 561-565
Article title

Cytotoxic effects of cladribine and tezacitabine toward HL-60.

Content
Title variants
Languages of publication
EN
Abstracts
EN
The aim of the study was to determine the relation between the cytotoxic and cytostatic effects of tezacitabine and cladribine on a HL-60 cell line and the time of exposure of cells to these drugs. Cell viability and induction of apoptosis were assessed using flow cytometry methods. Apoptosis was confirmed by direct microscopic observation. Growth inhibition was examined by cell counting. After 24 h incubation tezacitabine was equally or less toxic compared to cladribine. However, toxicity of tezacitabine strongly rose after 48 h incubation leading to massive cell death at doses much lower than those of cladribine. Assessment of the effect of increased exposure time on the clinical efficacy of tezacitabine is indicated.
Year
Volume
52
Issue
2
Pages
561-565
Physical description
Dates
revised
2005-01-25
accepted
2005-02-10
References
  • Cohen JD, Strock DJ, Teik JE, Katz TB, Marcel PD (1997) Cancer Lett 116: 167-175.
  • Faderl S, Garcia-Manero G, Thomas DA, Cortes J, O’Brien S, Giles FJ, Koller CA, Beran M, Verstovsek S, Kwari M, Ghandi V, Plunkett W, Kantarjian HM (2001) Blood 98: 2493.
  • Faderl S, Gandhi V, Kantarjian H, Plunkett W (2002) In Cancer Chemot Biol Resp Mod. Ann 20. Giaccone G, Schilsky R, Sondel P, eds, pp 37-58. Elsevier Science B.V.
  • Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O’Dwyer PJ (2003) Cancer 97: 1985-1990.
  • Galmarini CM, Mackey JR, Dumontet C (2001) Leukemia 15: 875-890.
  • Grieb P, Koronkiewicz M, Skierski JS (2000) Acta Biochim Polon 47: 165-171.
  • Grieb P, Kamienowski J, Janisz M, Kusnierczyk P, Kawiak J, Hoser G, Chrapusta SJ (2001) Int J Hematol 74: 421-427.
  • Gollard R, Miller WE, Piro LD, Saven A (1997) Leuk Lymphoma 28: 183-185.
  • Griffig J, Koob R, Blakley RL (1989) Cancer Res 49: 6923-6928.
  • Karlsson K, Stromberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Larfars G, Cristiansen I, Nilsson G, et al. (2002) Br J Haematol 116: 538-548.
  • Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D (1999) Haematologica 84: 22-25.
  • Liliemark J (1997) Clin Pharmacokinet 32: 120-131.
  • Liliemark J, Juliusson G (1995) Clin Cancer Res 1: 385-390.
  • McCarthy JR, Matthews DP, Stemerick DM, Huber EW, Bey P, Lippert BJ, Snyder RD, Sunkara P (1991) J Am Chem Soc 113: 7439-7440.
  • Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. (1991) J Natl Cancer Inst 83: 757-766.
  • Piro LD, Carrera CJ, Carson DA, Beutler E (1990) N Engl J Med 322: 1117-1121.
  • Robak T, Gora-Tybor J, Krykowski E, Walewski JA, Borawska A, Pluzanska A, Potemski P, Hellmann A, Zaucha JM, Konopka L, et al. (1997) Leuk Lymphoma 26: 99-105.
  • Robak T, Blasinska-Morawiec M, Blonski J, Hellmann A, Halaburda K, Konopka L, Kotlarek-Haus S, Potoczek S, Hansz J, Dmoszynska A, et al. (1999) Eur J Haematol 62: 49-56.
  • Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ (2002) Clin Cancer Res 8: 2828-2834.
  • Ross DD, Joneckis CC, Ordonez JV, Sisk AM, Wu RK, Hamburger AW, Nora RE (1989) Cancer Res 49: 3776-3782.
  • Saven A, Piro LD (1994) Ann Intern Med 120: 784-791.
  • Seley KL (2000) Curr Opin Investig Drugs 1: 135-140.
  • Skierski JS, Koronkiewicz M, Grieb P (1999) Cytometry 37: 302-307.
  • Takahashi T, Nakashima A, Kanazawa J, Yamaguchi K, Akinaga S, Tamaoki T, Okabe M (1998) Cancer Chemother Pharmacol 41: 268-274.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv52i2p561kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.